Theseus Pharmaceuticals, Inc.
(NASDAQ GS: THRX)
Rigrodsky Law, P.A. is investigating Theseus Pharmaceuticals, Inc. (“Theseus”) regarding possible breaches of fiduciary duties and other violations of law related to Theseus’ agreement to be acquired by Concentra Biosciences, LLC. Under the terms of the agreement, Theseus shareholders will receive between $3.90 and $4.05 per share in cash plus one contingent value right.